GlassScriptPhysician profile
Beverly R Encarnacion
NPI 1659331270
$6,285.10
in general payments reported to CMS, 2019-2025
34 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $1,523 · 2021: $1,365 · 2022: $240 · 2023: $225 · 2024: $661 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,076.96 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,001.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $667.93 | 2019-2025 | |
| Novo Nordisk INC | $511.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $428.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.22 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $288.32 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $286.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $283.03 | 2019-2021 | |
| Allergan, INC. | $197.00 | 2019-2020 | |
| Astellas Pharma US INC | $187.97 | 2019-2020 | |
| Exact Sciences Corporation | $127.24 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $89.52 | 2025 | |
| Biogen, INC. | $76.38 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $68.17 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $61.84 | 2021 | |
| Abbvie INC. | $57.03 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $56.94 | 2020 | |
| Amgen INC. | $54.83 | 2021-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $47.97 | 2022 | |
| Abbott Laboratories | $44.63 | 2020-2021 | |
| Boston Scientific Corporation | $32.08 | 2025 | Watchman Access System |
| Inspire Medical Systems, INC. | $29.23 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $24.41 | 2020-2022 | |
| Sanofi Pasteur INC. | $24.31 | 2019 | |
| Si-Bone, INC. | $22.44 | 2024 | |
| Horizon Therapeutics Plc | $21.94 | 2023 | Krystexxa |
| Nevro Corp. | $18.94 | 2024 | Senza |
| Portola Pharmaceuticals, LLC | $18.18 | 2019 | |
| Melinta Therapeutics, LLC | $15.55 | 2019 | |
| Sumitomo Pharma America, INC. | $15.47 | 2025 | Gemtesa |
| Medtronic Minimed, INC. | $14.00 | 2020 | |
| Genentech USA, INC. | $13.81 | 2019 | |
| Medtronic Vascular, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Encarnacion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.